Fear memory encoding, the process responsible for persistent reactions to trauma-associated cues, is influenced by a sparse but potent population of inhibitory cells called parvalbumin-interneurons (PV-INs) in the amygdala, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online July 14 in the journal Neuron.
The Mount Sinai study focused on identifying the synaptic connections between inhibitory PV-INs, sensory pathways and neighboring principal neurons in the basolateral amygdala, a brain region involved in detecting and responding to dangerous situations.
Stimuli encountered during a traumatic event can elicit strong emotional reactions long after the threat has subsided. These emotional memories are thought to be encoded through changes in the neural connections, or synapses, within the basolateral amygdala that provide outputs to other brain areas, controlling the so-called "fight or flight" response. These principal neurons increase their activity when an animal learns a threatening stimulus association. At other times, these cells are very quiet, despite their ongoing bombardment by sensory stimulation.
"Our study is the first to show that this default silencing may, in part, be attributable to a sparse population of inhibitory PV-INs," says Roger Clem, PhD, Assistant Professor of Neuroscience and Psychiatry at the Icahn School of Medicine at Mount Sinai and lead investigator of the trial. "The complex anatomy of these cells may allow them to function like master regulators on a hair trigger, springing into action to suppress their neighbors when they detect even the slightest sensory perturbation."
To investigate whether fear learning alters PV-IN properties and their silencing effect on surrounding neurons, the Mount Sinai team introduced fear conditioning in a mouse model, pairing an auditory tone with a subsequent aversive foot shock. They found that when animals acquire a fear memory, the suppressive influence of PV-INs is relieved, allowing the fear system to respond more vigorously when the auditory stimulus is re-encountered in order to trigger a fight-or-flight response.
All sensations, movements, thoughts, memories and feelings are the result of signals that pass through nerve cells (neurons), the primary functional unit of the brain and central nervous system. When a signal passes from the cell body to the end of the cell axon that stretches away from the cell body, chemicals known as neurotransmitters are released into the synapse, the place where signals are exchanged between cells. The neurotransmitters then cross the synapse and attach to receptors on the neighboring cell, which can change the properties of the receiving cell.
Found throughout the brain and produced by neurons, gamma aminobutyric acid (GABA) is an inhibitory neurotransmitter that binds to GABA receptors, making the neighboring neuron less excitable. Fear-related disorders like anxiety and post-traumatic stress disorder (PTSD) are thought to partly result from an imbalance of excitatory and inhibitory nerve cells in the basolateral amygdala.
The current study team investigated GABA-synthesizing PV-INs after fear conditioning. Specifically, using electrophysiological and optogenetic techniques, the research team found that both input to and output from these cells was decreased after fear learning. In addition, the team found that memory encoding specifically affected PV-INs that respond most robustly to sensory input and that are thus uniquely positioned to regulate emotional reactivity.
The study findings indicate that inhibitory plasticity is a normal consequence of memory encoding and when dysregulated, it could lead to the hyper excitability of the amygdala, a hallmark of PTSD.
"Further investigation of the function of these PV-IN circuits under various stress paradigms may identify which of the processes we describe might be involved in pathological fear expression and ultimately, could establish cellular targets for reducing inappropriate amygdala responses and subsequent fear behaviors," says Dr. Clem.
This research was supported by NIH grants MH105414 (R.L.C.) EY026053 (H.M.) and MH096678 (E.K.L.); a NARSAD Young Investigator Award (R.L.C.); and The Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care.
The System includes approximately 7,000 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2015-2016 "Best Hospitals" issue of U.S. News & World Report. Mount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology, while Mount Sinai Beth Israel is ranked regionally.
For more information, visit http://www.